In one paragraphArticle in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Muhammad AzhariDepartment of Pharmacochemistry, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.ORCID 0000-0003-3966-582X Shinnosuke IsshikiLaboratory of Natural Products for Drug Discovery, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita 565-0871, Japan.
Riku HorinouchiLaboratory of Natural Products for Drug Discovery, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita 565-0871, Japan.
Marlia SinggihDepartment of Pharmacochemistry, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
Masayoshi AraiLaboratory of Natural Products for Drug Discovery, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita 565-0871, Japan.ORCID 0000-0003-2771-1948 Afrillia Nuryanti GarmanaDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
Rika HartatiDepartment of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
Yuni Elsa HadisaputriDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.ORCID 0000-0002-8087-9152 Nunung YuniartiDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
Elin JuliantiDepartment of Pharmacochemistry, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.ORCID 0000-0002-5504-6140 Funding
Japan Society for the Promotion of Science Grant Number 21H02069Lembaga Pengelola Dana Pendidikan EQUITY Program Contract No. 9891/IT1.B07.1/TA.00/2025
6 · The paper itselfAbstract
Tuberculosis therapy is prolonged partly because dormant subpopulations of
Indexed as
Antitubercular AgentsMycobacterium smegmatisPyrazinesAquatic OrganismsAspergillusIronAntitubercular AgentsIronPyrazinesantimycobacterialhydroxamate pyrazinoneshypoxiairon sequestrationmarine-derived AspergillusMycobacterium smegmatisnon-replicating persistence
Identifiers
PMID42505976
PMCPMC13412789
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390